From Inhaled Insulin to Oral Bacteria: Ongoing Clinical Trials of Alzheimer’s Disease Biomarkers, Therapeutic Targets Show Promise

As the year 2020 approaches, Alzheimer’s disease research is more generously funded and richly infused with biomarker studies and clinical trials addressing a diversity of therapeutic targets and approaches that move beyond anti-amyloid therapies — to tau, for instance, and to neuroinflammation and neurodegeneration — than it was a decade ago.